Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin

Alsius, Mercè; Ferri, María; Buxó, María; López, Carme; Serra, Isabel; Queralt, Xavier; Acero, Doroteo

doi:10.1016/j.gastre.2019.02.004

Cited by 4 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that anti-RR positivity rates range from 14.1% to 38%. 7,19 A study by Alsius et al 20 found that the rate of anti-RR in patients with HCV infection was 9.2% with similar treatment groups, whereas in our study this was 15.16%. In the long-term study of da Silva Sacerdote et al 18 this rate was 23% in patients who had received PEG-IFN/RBV.…”

Section: Discussioncontrasting

confidence: 63%

“…Studies have shown that anti‐RR positivity rates range from 14.1% to 38% 7,19 . A study by Alsius et al 20 . found that the rate of anti‐RR in patients with HCV infection was 9.2% with similar treatment groups, whereas in our study this was 15.16%.…”

Section: Discussioncontrasting

confidence: 58%

“…The rate of anti-RR was 25.9% in patients who received PEG-IFN/RBV before DAA treatment in Alsius et al 20 study and this rate was 16.3% (9/55) in our study. In contrast to our study results, the rate of anti-RR in Alsius et al 20 was higher in male patients but not statistically significant. In their study, it was shown that PEG-IFN exposure and duration of treatment with RBV were associated with anti-RR.…”

Section: Discussionsupporting

confidence: 53%

“…In accordance with the literature, the first or last treatment regimens of all patients with anti-RR positivity included PEG-IFN/RBV. Alsius et al 20 also found that the anti-RR was negative in patients receiving DAA. The rate of anti-RR was 25.9% in patients who received PEG-IFN/RBV before DAA treatment in Alsius et al 20 study and this rate was 16.3% (9/55) in our study.…”

Section: Discussionmentioning

confidence: 91%

“…Alsius et al 20 also found that the anti-RR was negative in patients receiving DAA. The rate of anti-RR was 25.9% in patients who received PEG-IFN/RBV before DAA treatment in Alsius et al 20 study and this rate was 16.3% (9/55) in our study. In contrast to our study results, the rate of anti-RR in Alsius et al 20 was higher in male patients but not statistically significant.…”

Section: Discussionmentioning

confidence: 91%

See 4 more Smart Citations

The relevance between anti‐rods/rings antibody and different treatment regimens in chronic hepatitis C virus infection

Peker

Şener

Topal

et al. 2021

Microbiology and Immunology

View full text Add to dashboard Cite

The antibodies and other issues associated with immunity in chronic hepatitis C virus (HCV) have been widely investigated, especially non-organ-specific antinuclear antibodies. Rods-rings (RR) antibody patterns are frequently observed due to pegylated IFN-α (PEG-IFN)/ribavirin (RBV) treatment by indirect immunofluorescence (IIF). We evaluated the relevance between anti-RR and PEG-IFN/RBV and/or direct-acting antiviral (DAA) regimens in chronic HCV. Sampling was done after achieving a sustained virological response (SVR) for 178 patients (aged >18 years). Patients were grouped according to treatment protocols (Group 1 [G1]: PEG-IFN/RBV [n = 53], Group 2 [G2]: PEG-IFN/RBV and Telaprevir or Boceprevir [n = 31], Group 3 [G3]: second-and third-wave DAA and previously received PEG-IFN/RBV (n = 38), and Group 4 [G4]: second-and third-wave DAA [n = 56]). Anti-RR was investigated by IIF (Euroimmun AG) test. Overall, 27 (15.16%) patients were anti-RR positive and received PEG-IFN/RBV. The numbers of anti-RR positivity for G1/2/3/4 (%) were 16/3/8/0 (30.2/9.6/21/0), respectively (p < .001). The anti-RR positivity rate for G1/2/3 was 22.13% (27/122, p = .088). Anti-RR was positive in 17.5% (11/63) of G1/2/3 patients who did not achieve SVR after the first treatment. This rate was 27.1% (16/59) in patients with SVR after the first treatment in G1/2 and there was no difference between these two classified groups in terms of antibody titers (p = .915). Anti-RR was detected up to 172 months after SVR. In summary, anti-RR was positive in high rates in patients receiving PEG-IFN/RBV therapy. Frequent monitoring is needed during patient follow-up to get more data on the relationship between anti-RR titer, treatment regimens, and SVR.

show abstract

Section: Discussioncontrasting

confidence: 63%

Section: Discussioncontrasting

confidence: 58%

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 91%

See 3 more Smart Citations

The relevance between anti‐rods/rings antibody and different treatment regimens in chronic hepatitis C virus infection

Peker

Şener

Topal

et al. 2021

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

The value of anti-rods and rings antibodies in patients with nonhepatitis virus infection

Zhang¹,

Ji²,

Yang³

et al. 2021

Medicine

View full text Add to dashboard Cite

The aim of this study was to retrospectively investigate the clinical significance of anti-rods and rings (anti-RR) antibodies in nonhepatitis virus infection patients from Southwest China. Anti-RR antibodies were determined by indirect immunofluorescence assay in a group of 19,935 individuals with antinuclear antibodies test from January 2017 to December 2019. The laboratory and clinical data were collected. Finally, 66 samples with anti-RR antibodies (0.33%) were detected. In Wilcoxon rank sum test, gamma glutamyl transferase ( Z = −3.364, P = .001), alpha-l-fucosidase (AFU) ( Z = −2.312, P = .021), uric acid ( Z = −1.634, P = .047) and red blood cell distribution width ( Z = −2.285, P = .022) were higher in metabolic disease group than nonmetabolic disease group. In independent-samples t test, endogenous creatinine clearance was higher in metabolic disease group than nonmetabolic disease group ( t = 2.061, P = .045). During the follow-up period of 37 patients with anti-RR antibodies for 1 to 60 months, the titers of anti-RR were significantly increased in the metabolic disease group ( Z = −2.346, P = .019). In binary logistic regression analysis, triglycerides (odds ratio 3.679, 95% confidence interval 1.467–24.779, P = .048) was associated with elevated titers of anti-RR antibodies. In summary, anti-RR in non-hepatitis patients may be a manifestation of metabolic disorders, and has a certain correlation with routine laboratory indicators, which is worthy of the attention from clinicians.

show abstract

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis

Zhang

Bao

et al. 2022

Medicine

View full text Add to dashboard Cite

The study was to investigate the clinical characteristics and significance of antinuclear antibody (ANA) cytoplasmic patterns in ANCA-associated vasculitis (AAV) from Southwest China. A retrospective study including 232 AAV patients from Peoples Hospital of Deyang City was performed. These included 115 patients with ANA cytoplasmic pattern as observation group and 117 patients without ANA cytoplasmic pattern as control group. Chest involvement (60.00 vs 46.15, P = .035), cardiovascular involvement (5.21 vs 29.91, P < .001), and renal involvement (37.39 vs 77.78, P = .001) were different between groups. Total protein (69.55 vs 64.01, P < .001), triglyceride (1.41 vs 1.18, P = .023), mean cell volume (89.76 vs 87.59, P = .040), and estimated glomerular filtration rate (76.67 vs 50.87, P = .035) were higher in ANA cytoplasmic patterns group. Creatinine (73.00 vs 117.50, P = .011), white blood cell (6.93 vs 8.86, P = .001), platelet (196.0 vs 239.0, P = .017), anti-myeloperoxidase (2.44 vs 3.42, P = .042), and anti-proteinase 3 (1.00 vs 4.93, P = .007) were lower in this group. In multivariate analysis, creatinine (odds ratio [OR] = 1.21, 95% confidence interval [CI]: 1.06–1.38), triglyceride (OR = 1.97, 95% CI: 1.10–3.48), and anti-myeloperoxidase (OR = 1.64, 95% CI: 1.37–1.95) were independent risk factors of AAV renal involvement. Total protein (OR = .95, 95% CI: 0.91–0.99) was an independent protective factor of AAV renal involvement. Chi-square test showed that speckled pattern was different among anti-neutrophil cytoplasmic antibody patterns ( χ 2 = 18.526, P < .001). In summary, HEp-2 cell cytoplasmic patterns have certain clinical significance in AAV, which is a new exploration of the clinical value of ANA.

show abstract

Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin

Cited by 4 publications

References 13 publications

The relevance between anti‐rods/rings antibody and different treatment regimens in chronic hepatitis C virus infection

The relevance between anti‐rods/rings antibody and different treatment regimens in chronic hepatitis C virus infection

The value of anti-rods and rings antibodies in patients with nonhepatitis virus infection

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis

Contact Info

Product

Resources

About